PMID- 17068620
OWN - NLM
STAT- MEDLINE
DCOM- 20080527
LR  - 20171116
IS  - 1671-167X (Print)
IS  - 1671-167X (Linking)
VI  - 38
IP  - 5
DP  - 2006 Oct 18
TI  - [Monocyte chemoattractant protein-1 and its correlation with lipoprotein in 
      polycystic ovary syndrome].
PG  - 487-91
AB  - OBJECTIVE: To measure serum monocyte chemoattractant protein-1 (MCP-1) levels and 
      study its associations with lipoproteins in patients with polycystic ovary 
      syndrome (PCOS). METHODS: Sixty-five PCOS women and 20 ovulating normal women 
      with body mass index (BMI) < 25 kg/m2 as controls were recruited. PCOS women were 
      divided to two groups: 27 BMI >or = 25 kg/m2 patients as obese group; 38 BMI < 25 
      kg/m2 as non-obese group. Serum MCP-1 was assayed by enzyme-linked immunosorbent 
      assays (ELISA). Serum prolactin (PRL), follicle stimulating hormone (FSH), 
      luteinizing (LH), estradiol (E2) and testosterone (T) were assayed by 
      chemoluminescence method. Serum androstenedione (A) was assayed by radioimmunity 
      method in patients. And triglycerides (TG), total cholesterol (TC), apoprotein A 
      (ApoA), apoprotein B (ApoB) , lipoprotein (a) [LP(a)], high density lipoprotein 
      (HDL) and low density lipoprotein (LDL) cholesterol (HDL-C and LDL-C) were 
      measured. RESULTS: MCP-1 (P = 0.001) and ApoB (P = 0.018) levels were found to be 
      significantly increased in PCOS groups compared with that of controls, but the 
      ratio of ApoA/ ApoB was significantly decreased in groups PCOS (P = 0.015). PCOS 
      obese group had markedly higher MCP-1 serum levels than non-obese group (P = 
      0.012), and MCP-1 serum levels in PCOS non-obese group higher than controls (P = 
      0.03). Univariate analysis revealed that serum MCP-1 levels were significantly 
      and positively correlated with BMI (r = 0.350, P = 0.001), LH(r = 0.262, P = 
      0.016), TG (r = 0.480, P = 0.000) and ApoB (r = 0.289, P =0.008); but 
      significantly and negatively correlated with the ratio of ApoA/ ApoB (r = -0.282, 
      P = 0.009). Partial correlation showed that serum MCP-1 levels were correlation 
      with LH (r = 0.2577, P = 0.020) and TG (r = 0.4611,P = 0.000). Multiple 
      regression analysis showed that MCP-1 levels was influenced by BMI and TG. 
      Furthermore, TG showed more effect on MCP-1 levels. CONCLUSION: PCOS obese and 
      non-obese patients had higher serum MCP-1 levels than controls. MCP-1 was 
      correlated with BMI, LH ,TG, ApoB and the ratio of ApoA/ ApoB. BMI and TG were 
      two major determining factors of MCP-1 in patients with PCOS. Furthermore,TG had 
      more effect on MCP-1 levels. Based on the above findings, we presume that MCP-1 
      is likely to participate in the pathophysiology and long-term complication of 
      PCOS.
FAU - Hu, Wei-hong
AU  - Hu WH
AD  - Department of Obstetrics and Gynecology, Peking University Third Hospital, 
      Beijing 100083,China.
FAU - Qiao, Jie
AU  - Qiao J
FAU - Zhao, Shu-yun
AU  - Zhao SY
FAU - Zhang, Xiao-wei
AU  - Zhang XW
FAU - Li, Mei-zhi
AU  - Li MZ
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Beijing Da Xue Xue Bao Yi Xue Ban
JT  - Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health 
      sciences
JID - 101125284
RN  - 0 (Apolipoproteins A)
RN  - 0 (Apolipoproteins B)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Lipoproteins)
RN  - 0 (Triglycerides)
RN  - 9002-67-9 (Luteinizing Hormone)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Apolipoproteins A/blood
MH  - Apolipoproteins B/blood
MH  - Body Mass Index
MH  - Chemokine CCL2/*blood
MH  - Cholesterol/blood
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Lipoproteins/*blood
MH  - Luteinizing Hormone/blood
MH  - Obesity/*blood/complications
MH  - Polycystic Ovary Syndrome/*blood/complications
MH  - Regression Analysis
MH  - Triglycerides/blood
EDAT- 2006/10/28 09:00
MHDA- 2008/05/28 09:00
CRDT- 2006/10/28 09:00
PHST- 2006/10/28 09:00 [pubmed]
PHST- 2008/05/28 09:00 [medline]
PHST- 2006/10/28 09:00 [entrez]
PST - ppublish
SO  - Beijing Da Xue Xue Bao Yi Xue Ban. 2006 Oct 18;38(5):487-91.